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145 Nutritional status and lung function in CF patients with
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M.V. Guillot1,2, D. Claeyes1, M. Ellafﬁ1, R. Leclerc1, M. Laurans1, G. Zalcman1,
J. Brouard1. 1CHG R. Bisson, Lisieux CF Center, Lisieux, France; 2CHU Coˆte de
Nacre, Caen CF Centers, Caen, France
In a previous work (Journal of Cystic Fibrosis, 2008, 7, S45) we had shown
lung function deterioration with no clonal relationship and no Panton-Valentine
leucocidine in our CA-MRSA CF population.
This retrospective longitudinal cohort study includes 31 patients data (2 years
4 months, 27 years 6 months − 2003–2007) studied through monitored parame-
ters (CF genotype, clinical manifestations, nutritional status, lung function) using
regression linear analysis methods to assess yearly decline in FEV1 and Z score of
Body Mass Index.
Results:
1. An overall 58% Staphylococcus prevalence is demonstrated in patients: with a
CA-MSA of 48% prevalence.
– CA-MRSA prevalence increases from 3.8% (2003) to 16.1% (2007), with an
average acquisition age of 15.4 years, within a 4 years interval.
– High AB resistance rates are observed both for AC-MSSA and AC-MRSA,
respectively: 66.7% and 91.7% for erythromycin, 20.8% and 29.2% for ri-
fampicin, 12.5% and 25% for fucidic acid, 22.2% and 29.2% for cotrimoxazole
and 25.5% and 91.7% for quinolones.
– CA-MRSA colonization is correlated with a higher yearly average decline rate
of FEV1 as compared with non-colonized patients; in such patients the yearly
decline in FEV1 is −7.89%.
2. CA-MRSA colonization is correlated with a Z score decline: −0.67 standard
deviations versus +0.06 standard deviations in CA-MSSA patients.
Conclusion: Although the observation period is limited and the number of patient
studies does not permit extensive statistical analysis, this work suggests a patho-
genetic deleterious impact of CA-MRSA colonization on nutritional status and lung
function.
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CF patients suffer from chronic lung infections caused by facultative and obligate
anaerobic bacteria. We investigated the role of periodontal pockets as possible
sources for CF lung infections. In 11 CF patients and in 11 controls facultative
and obligate anaerobic bacteria were identiﬁed using biochemical identiﬁcation
systems in sputum (CF patients only) and periodontal pockets. Antibiotic sensitivity
proﬁles were obtained using e-tests for piperacillin/tazobactam (TZP), ceftazidime
(CAZ), meropenem (MRP), metronidazole (LZ), colistin (CS), clindamycin (CD)
and azithromycin (AZM). 9 CF patients produced sputum. In 4 of them (44.4%),
identical facultative anaerobes (Pseudomonas aeruginosa, Staphylococcus aureus,
Burkholderia cepacia) were found in periodontal pockets and in sputum. In all
patients (100%), identical obligate anaerobic strains were found in both compart-
ments (Streptococcus, Staphylococcus, Peptostreptococcus and Clostridium spp.).
In periodontal pockets, percentages of resistant strains (facultative plus obligate
anaerobes) were similar in CF-patients and controls: TZP 36.9 vs. 43.7, CAZ
67.6 vs. 62.3, MRP 31.9 vs. 17.0, LZ 19.1 vs. 13.5, CS 24.3 vs. 20.8, CD
8.4 vs. 1.9, AZM 56.1 vs. 53.8. Identical genera were found in both CF and
control periodontal pockets. The detection of identical obligate anaerobic genera
with similar resistance patterns in CF patients and controls argues for ubiquitous
appearance of these bacteria. The simultaneous conﬁrmation of identical facultative
and obligate anaerobic genera in CF periodontal pockets and sputum samples
suggests periodontal pockets as a possible source for lung contamination with these
bacteria.
147 Clinical effect of additional systemic antibacterial agent in
pulmonary exacerbation management
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Introduction: Pulmonary exacerbations (PE) are occasionally managed with more
than the standard two antibiotics combination. The effect of this practice is
unknown.
Methods: A review of PE occurring over 3 years managed with additional systemic
antibacterials (excluding oral anti-Staphylococcal agents) was undertaken. Out-
comes were compared to exacerbations in the same patient occurring immediately
before and after identiﬁed episodes, managed with 2 agents.
Results: Twenty-eight patients had 37 PE managed with additional systemic
agent(s). Outcomes were compared to 54 PE events occurring immediately before
(29) or after (25) identiﬁed episodes. Patients were 68% F508del homozygous, 25%
had CF-related diabetes and 36% were receiving enteral nutrition. Patients identiﬁed
had a median FEV1 of 45%, BMI of 20.2 and experienced 3.5 exacerbations/year.
Patients were chronically infected with B. cenocepacia 10/28, P. aeruginosa 19/28,
S. aureus 3/28 and S. maltophilia 2/28. Three systemic agents were used in 33
episodes, 4 in 2 episodes and 5 in 1 episode. Chloramphenicol was used 13 episodes,
ciproﬂoxacin 18, trimethoprim-sulfamethoxazole 4, colistin 3, doxycycline 2, and
an anti-pseudomonal beta-lactam in 2. Additional agents did not improve outcomes
with respect to treatment duration [14 days vs 13, p = 0.46], time to next exacer-
bation [64 days vs. 52, p = 0.280], FEV1 improvement [8% vs 7%, p = 0.98] nor
resolution of inﬂammatory markers. Subgroup analysis did not show a beneﬁt for
any organism, antibiotic or resistance proﬁle.
Conclusion: Additional antibacterial agents beyond the usual two drug regimen
used to treat PE do not result in improved clinical outcome.
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Background: Since 2000 adult CF patients chronically infected with Pseudomonas
aeruginosa (PA) are treated with macrolide maintenance therapy (MMT). In surveys
an increased incidence of S. aureus resistant to macrolides has been related to MMT.
Methods: We made a comparison between 1997 (before introduction of MMT)
and 2007 of pathogens in sputum isolates of adult CF patients. Isolates of 1997
and 2007 were analysed. Patients with data in 1997 and 2007 were included in a
subgroup analysis with and without MMT.
Results: In 1997 154 patients (55% male, age 27.7 yrs, BMI 20.5, FEV1 predicted
54%, all medians) and in 2007 160 patients (53% male, age 34.1 yrs, BMI 21.6,
FEV1 predicted 57.5%) were included. Presence of PA remained stable (66.9 resp
67.5%), presence of S. aureus declined from 52.6% to 32.5% and H. inﬂuenzae
from 23.4 to 5.6%. Resistance of S. aureus towards macrolides increased from
14.8% to 59.6% in the entire patient group.
In those patients treated from 1997 on toward 2007 resistance rose from 12 to 86%
and was equally distributed among patients treated with MMT and those not treated
with MMT.
Conclusion: Introduction of macrolide maintenance therapy in patients colonised
with PA was accompanied by a reduction in prevalence of S aureus and H. inﬂuenzae
in sputum isolates and with a marked increase in macrolide resistance of S. aureus.
Resistance towards macrolides however occurred in patients on MMT, but also in
patients not on MMT in the same magnitude. Whether this is due to the low numbers
of positive S. aureus cultures, to cross-resistance or to the use of macrolides apart
from MMT needs further investigation.
